CytoTronics enables optics-free imaging for drug discovery through its complementary metal-oxide-semiconductor (CMOS) electronics platform. Building upon a suite of innovations licensed from Harvard University, CytoTronics’s technology measures and manipulates live cells to produce real-time, high resolution electrical and electrochemical cell-based assays. By providing unique single-cell resolution readouts that are not currently available in today’s cell-based drug screening market, CytoTronics is enhancing the accuracy of cell-biology information that can be used to revolutionize drug discovery.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $22.75M
Founded date: 2020
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.09.2024 | Seed | $13.5M | - |
| 30.04.2022 | Seed | $9.25M | Anzu Partn... |
Mentions in press and media 8
| Date | Title | Description |
| 07.09.2024 | CytoTronics Secures $13.5 Million to Revolutionize Cell Biology | In the bustling world of biotechnology, CytoTronics has emerged as a beacon of innovation. The Boston-based company recently announced a significant milestone: a $13.5 million Series Seed 2 funding round. This infusion of capital is not jus... |
| 07.09.2024 | CytoTronics: Cell Biology Discovery Tech Company Raises $13.5 Million (Seed Extension) | CytoTronics, a pioneer of semiconductor-based platforms for discovery in cell biology, announced a $13.5 million seed extension financing and the appointment of Sameer Rohatgi of LYFE Capital to their Board of Directors. New investor LYFE C... |
| 05.09.2024 | CytoTronics Raises $13.5M in Series Seed 2 Financing | CytoTronics, a Boston, MA-based provider of semiconductor-based platforms for discovery in cell biology, raised $13.5M in Series Seed 2 funding. The Series Seed 2 round was led by new investor LYFE Capital, and existing investor Anzu Partne... |
| 30.04.2022 | CytoTronics Launches with $9.25 Million in Seed Funding to Revolutionize Drug Discovery and Phenotypic Screening | Harvard University spinout advances a unique complementary metal-oxide-semiconductor (CMOS)-powered drug discovery platform that opens a new dimension in cell-based screening CytoTronics, a biotechnology company building a next-generation c... |
| 29.04.2022 | CytoTronics Raises $9.25M in Seed Funding | CytoTronics, a Boston, MA-based biotechnology company, raised $9.25M in Seed funding. The round was led by Anzu Partners with participation from Milad Alucozai (BoxOne Ventures). The company intends to use the funds to advance its platform ... |
| 28.04.2022 | CytoTronics Launches With $9.25M Seed | BOSTON, MA, CytoTronics today announced it has raised $9.25 million in initial seed funding. >> Click here for more funding data on CytoTronics >> To export CytoTronics funding data to PDF and Excel, click here CytoTronic... |
| 28.04.2022 | Has Elon Musk already broken his merger agreement with Twitter? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Elon Musk has been tweeting this week in reference to the Twitter deal—which is, in fact, allowed... |
| - | CytoTronics | “CytoTronics allows you to visualize live cell function in real time and at scale using a revolutionary approach to studying cell biology, powered by microchips.” |